2023 Pancreatic Diseases Gordon Research Conference and Gordon Research Seminar
2023 Pancreatic Diseases Gordon Research Conference and Gordon Research Seminar
批准号:
10681581
负责人:
NABEEL El-BARDEESY
金额:
$0.6万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-04-28 至 2023-06-30
关键词:
Acinar CellAddressAlpha CellAreaAutoimmuneBiologicalBiological AssayBiologyCell CommunicationCell TherapyCell secretionCellsClinicalCollaborationsCommunicationCommunitiesDataDedicationsDevelopmentDiabetes MellitusDigestionDisciplineDiseaseDisparateDuctal Epithelial CellDuodenumEndocrineEndocrinologistEnvironmentEnzymesExocrine pancreasFellowshipFemaleFoodFosteringFunctional disorderGastroenterologistGene Expression RegulationGenerationsGeneticGenomicsGlucagonGlucoseGoalsHealthHealth systemHomeostasisHormonesHumanImageImmune systemImpairmentIn VitroInsulinInterdisciplinary StudyInternationalIslet CellIslets of LangerhansItalyLifeLinkMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMedicalMentorsMentorshipMetabolicModelingMolecularMusNatural regenerationOralOrganOrganoidsPancreasPancreatic AdenocarcinomaPancreatic DiseasesPancreatitisPhysiologicalPositioning AttributePostdoctoral FellowPreventionProcessResearchResearch PersonnelResolutionRisk FactorsRoleScientistSomatostatinStructure of beta Cell of isletStudentsSurgeonTimeTrainingUnderrepresented MinorityUnderrepresented PopulationsWorkWorkplacecareercareer developmentcell behaviorcell typechronic pancreatitiscomorbiditycomputerized toolsdesigndiversity and inclusionempowermentepidemiology studyexosomeextracellular vesicleshuman diseaseinsightinterdisciplinary approachisletlecturesmeetingsmicrobiomeminority investigatornovelnovel strategiespancreas developmentpancreatic cancer modelpancreatic cancer patientspancreatic juicepeerpharmacologicpostersprogramsrecruitresponsesymposiumtooltranslational approach
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Gordon Research Conferences (GRCs) are a group of prestigious, non-profit, international scientific conferences
that have been held since 1931. This R13 proposal relates to the GRC on Pancreatic Diseases: "Pancreatic
Diseases: Understanding cell behavior and communication” and the associated trainee-led Gordon Research
Seminar (GRS), held April 29 - May 5, 2023, in Lucca, Italy. Recent years have brought rapid advances in our
understanding of the molecular mechanisms underlying pancreatic development, regeneration, and malignant
transformation, as well as our ability to model these processes in mice and human cells. These studies have
revealed lineage relationships between the different pancreatic cell types and plasticity in response to
environmental influences. Moreover, epidemiological studies show a clear association between pancreatic
diseases, in particular between diabetes and pancreatic cancer. Yet, the mechanisms involved in the co-
occurrence of pancreatic diseases are poorly understood. This GRC aims to link the understanding of the biology
of the exocrine and endocrine pancreas to applications for human diseases. This conference is unique in that it
convenes experts from all aspects of pancreas biology as well as clinicians working on translational approaches
for diabetes, pancreatic cancer and pancreatitis. By providing a forum for the presentation and discussion of
cutting edge, unpublished concepts and approaches, the goal of this GRC is to stimulate discussion across
disciplines. This exchange will foster interdisciplinary approaches and promote exchange of ideas to lead to new
collaborations, as well as empower young scientists to showcase their work to peers and leaders in the field.
The upcoming, fifth Pancreatic Diseases GRC will focus on understanding cell behavior and communication in
pancreatic diseases with the goal of gaining insights into how the systemic and local environment impact
endocrine and exocrine cells in health and disease. The program that has been assembled is first-rate,
benefitting from the contribution of international world-class scientists engaged in research relevant to different
aspects of pancreatic diseases. The ultimate goal of the conference is the identification of novel concepts in
pancreatic diseases that might be exploitable for pharmacological and cell-based therapeutic approaches. As
for all GRCs, the guiding principle of this conference is the presentation of new, unpublished results and the free,
unhampered discussion that follows. Participation of young scientists is especially emphasized, with
opportunities of short talks and poster presentations. To further enhance career development opportunities, a
Gordon Research Seminar (GRS) has been integrated into this meeting. Taking place immediately prior to the
GRC proper, the GRS features posters and talks exclusively by trainees as well as mentorship sessions designed
to provide trainees with established mentors willing to help guide their careers. Together, this makes for a rare
platform to promote young researchers, integrate trainees into the interdisciplinary pancreatic disease research
community, and impact their career trajectory at a critical time in their training.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functions of mutant IDH in cholangiocarcinoma
-
批准号:10800231
-
项目类别:
-
资助金额:$65.35万
-
财政年份:2023
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10558954
-
项目类别:
-
资助金额:$12.77万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10338071
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10559707
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression
-
批准号:10738337
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2019
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
-
批准号:10443802
-
项目类别:
-
资助金额:$66.39万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10524240
-
项目类别:
-
资助金额:$11.65万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10337194
-
项目类别:
-
资助金额:$47.06万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
-
批准号:10083201
-
项目类别:
-
资助金额:$59.91万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
-
批准号:10208803
-
项目类别:
-
资助金额:$67.74万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Functions of the LKB1 tumor suppressor in control in metabolism and epigentics
-
批准号:10026739
-
项目类别:
-
资助金额:$6.3万
-
财政年份:2018
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8234112
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8437129
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:7937156
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
Development of Molecularly Targeted Imaging Agents for KRAS activity in vivo
-
批准号:8100370
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2010
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8137997
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8517597
-
项目类别:
-
资助金额:$32.61万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:7895069
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:8305030
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
TGF-beta Signaling in Pancreatic Cancer
-
批准号:7690358
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2008
-
负责人:NABEEL El-BARDEESY
-
依托单位:
海外基金